#China #Shanghai #radiopharmaceuticals #Sanyou Bio #Baiyunshan Xihe

Strategic Collaboration to Drive Innovations in Nuclear Medicine

On July 4, 2026, two leaders in the biopharmaceutical space, Sanyou Biopharmaceutical Co., Ltd. and Guangzhou Baiyunshan Xihe Health Pharmaceutical Co., Ltd., came together to announce a strategic collaboration that promises to revolutionize the field of radiopharmaceuticals. This partnership is set to harness the unique strengths of both companies, focusing on the co-development of innovative radiopharmaceuticals and radiodiagnostic products tailored for precision oncology.

The Vision Behind the Partnership

The joint effort intends to create an efficient and effective innovation chain, from the initial discovery of target molecules to the clinical application of these advanced therapies. By capitalizing on their respective expertise, the firms aim to enhance the precision, stability, and overall effectiveness of drug molecules critical to nuclear medicine. With a robust history of achievement and advanced technologies at both companies, this collaboration is anticipated to be a groundbreaking development in the healthcare sector.

Key Contributions from Both Parties

Sanyou Bio's strength lies in its AI-driven drug discovery technologies. Utilizing its proprietary AI-Super trillion antibody/molecule libraries and the Sanyou AI-Drug Accelerator (SAI-DA), Sanyou Bio will provide significant innovation power for discovering and optimizing high-performance antibodies and targeting molecules. These resources will be vital in developing new therapeutic solutions that address the pressing challenges in cancer treatment.

On the other side, Baiyunshan Xihe brings a wealth of knowledge in nuclear medicine, possessing end-to-end capabilities in producing medical radionuclides and manufacturing them under stringent requirements. The company’s expertise in radionuclide production and clinical translation will play a crucial role in moving partnered molecules through radiolabeling, evaluation, and preclinical studies, aimed at bringing innovative solutions quickly to market.

Goals of the Collaboration

The collaboration has set out to achieve three major objectives:
1. Creating a Comprehensive Innovation Loop
By integrating their collaborative research and development (RD) strategies, the companies plan to create a continuous and efficient loop for drug discovery that connects molecular discovery capabilities directly with radiopharmaceutical industrialization. This aims to significantly reduce the timeline from concept to candidate compounds.
2. Developing a Unique Product Portfolio
Leveraging Sanyou Bio's drug development experience alongside Baiyunshan Xihe's production capabilities in key medical radionuclides, the partnership seeks to produce globally competitive theranostics and radiodiagnostic products.
3. Cultivating an Innovative Industrial Ecosystem
By fostering integration and collaboration within the drug development community, the partners aim to elevate China's competitive edge in radiopharmaceuticals and support the advancement of the entire nuclear medicine sector.

Statements from Leadership

Liu Hong, Chairman and General Manager of Baiyunshan Xihe, expressed enthusiasm about the potential of this partnership, highlighting the company’s strong position in the nuclear medicine industry and its comprehensive capabilities from production to clinical services.

Dr. Lang Guojun, Founder and CEO of Sanyou Bio, emphasized that this collaboration aligns with the company's mission to facilitate drug development globally, and he sees it as a pivotal step in bridging cutting-edge technologies with real-world clinical applications.

The Path Ahead

As they embark on this strategic initiative, both companies are eager to explore further collaborations that could redefine the landscape of radiopharmaceutical development. With a commitment to innovation, Sanyou Bio and Baiyunshan Xihe aim to establish themselves as pioneers in advancing effective therapeutic options for patients worldwide.

About Sanyou Bio

Headquartered in Shanghai, Sanyou Bio is a trailblazer in biopharmaceutical technology, dedicated to simplifying the process of drug development and addressing core challenges at the earliest stages of innovation. The firm is widely recognized for its integral role in advancing cutting-edge drug discovery and development efforts across the globe.